Inhibrx Biosciences, Stock Debt To Equity
| INBX Stock | USD 21.60 0.32 1.46% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Inhibrx Biosciences,'s long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.06 | 0.06 |
Inhibrx | Debt To Equity | Build AI portfolio with Inhibrx Stock |
Inhibrx Biosciences, Company Debt To Equity Analysis
Inhibrx Biosciences,'s Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Inhibrx Biosciences, Debt To Equity | 4.22 % |
Most of Inhibrx Biosciences,'s fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibrx Biosciences, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inhibrx Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Inhibrx Biosciences, is extremely important. It helps to project a fair market value of Inhibrx Stock properly, considering its historical fundamentals such as Debt To Equity. Since Inhibrx Biosciences,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibrx Biosciences,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibrx Biosciences,'s interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Inhibrx Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Inhibrx Biosciences, has a Debt To Equity of 4.221%. This is 92.12% lower than that of the Biotechnology sector and 78.2% lower than that of the Health Care industry. The debt to equity for all United States stocks is 91.33% higher than that of the company.
Inhibrx Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibrx Biosciences,'s direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inhibrx Biosciences, could also be used in its relative valuation, which is a method of valuing Inhibrx Biosciences, by comparing valuation metrics of similar companies.Inhibrx Biosciences, is currently under evaluation in debt to equity category among its peers.
Inhibrx Biosciences, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibrx Biosciences,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibrx Biosciences,'s managers, analysts, and investors.Environmental | Governance | Social |
Inhibrx Fundamentals
| Return On Equity | 0.41 | ||||
| Return On Asset | -1.07 | ||||
| Profit Margin | 8,615 % | ||||
| Current Valuation | 110.19 M | ||||
| Shares Outstanding | 14.48 M | ||||
| Shares Owned By Insiders | 27.19 % | ||||
| Shares Owned By Institutions | 68.11 % | ||||
| Number Of Shares Shorted | 898.44 K | ||||
| Price To Book | 2.33 X | ||||
| Price To Sales | 1,101 X | ||||
| Revenue | 200 K | ||||
| Gross Profit | (200.61 M) | ||||
| EBITDA | 1.7 B | ||||
| Net Income | 1.69 B | ||||
| Cash And Equivalents | 176.38 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 8.05 M | ||||
| Debt To Equity | 4.22 % | ||||
| Current Ratio | 7.51 X | ||||
| Book Value Per Share | 6.52 X | ||||
| Cash Flow From Operations | (194.41 M) | ||||
| Short Ratio | 6.96 X | ||||
| Earnings Per Share | 119.02 X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 156 | ||||
| Beta | 2.88 | ||||
| Market Capitalization | 220.18 M | ||||
| Total Asset | 180.77 M | ||||
| Retained Earnings | (106.13 M) | ||||
| Working Capital | 119.67 M | ||||
| Net Asset | 180.77 M |
About Inhibrx Biosciences, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibrx Biosciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibrx Biosciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibrx Biosciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inhibrx Stock Analysis
When running Inhibrx Biosciences,'s price analysis, check to measure Inhibrx Biosciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx Biosciences, is operating at the current time. Most of Inhibrx Biosciences,'s value examination focuses on studying past and present price action to predict the probability of Inhibrx Biosciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx Biosciences,'s price. Additionally, you may evaluate how the addition of Inhibrx Biosciences, to your portfolios can decrease your overall portfolio volatility.